Peripheral and local predictive immune signatures identified in a phase II trial of ipilimumab with carboplatin/paclitaxel in unresectable stage III or stage IV melanoma

BACKGROUND: Checkpoint blockade with ipilimumab provides long-term survival to a significant proportion of patients with metastatic melanoma. New approaches to increase survival and to predict which patients will benefit from treatment are needed. This phase II trial combined ipilimumab with carbopl...

Descripción completa

Detalles Bibliográficos
Autores principales: Jamal, Rahima, Lapointe, Réjean, Cocolakis, Eftihia, Thébault, Paméla, Kazemi, Shirin, Friedmann, Jennifer E., Dionne, Jeanne, Cailhier, Jean-François, Bélanger, Karl, Ayoub, Jean-Pierre, Le, Huy, Lambert, Caroline, El-Hajjar, Jida, van Kempen, Léon C., Spatz, Alan, Miller, Wilson H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696743/
https://www.ncbi.nlm.nih.gov/pubmed/29157311
http://dx.doi.org/10.1186/s40425-017-0290-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5696743/
https://www.ncbi.nlm.nih.gov/pubmed/29157311
http://dx.doi.org/10.1186/s40425-017-0290-x

Ejemplares similares